

This policy applies to the following:

✓	Standard Opt-in		ACSF		VF	✓	Marketplace
	Standard Opt-in NTMB	✓	PDPD		MMT		Medical Benefit
	Standard Opt-out		Generics First				Medical Benefit: Managed Medicaid

Reference #
2355-D

EXCEPTIONS CRITERIA GROWTH HORMONE

PREFERRED PRODUCTS: HUMATROPE and NORDITROPIN

POLICY

This policy informs prescribers of preferred products and provides an exception process for targeted products through prior authorization.

I. PLAN DESIGN SUMMARY

This program applies to the growth hormone products specified in this policy. Coverage for a targeted growth hormone product is provided based on clinical circumstances that would exclude the use of the preferred products and may be based on previous use of a product. The coverage review process will ascertain situations where a clinical exception can be made. This program applies to all members requesting treatment with a targeted product. Zorbtive and Serostim are excluded from the program.

Each referral is reviewed based on all utilization management (UM) programs implemented for the client.

Table. Growth Hormone Products

	Products
Preferred	<ul style="list-style-type: none"> • Humatrope (somatropin) • Norditropin (somatropin)
Targeted	<ul style="list-style-type: none"> • Genotropin (somatropin) • Nutropin AQ (somatropin) • Omnitrope (somatropin) • Saizen (somatropin) • Zomacton (somatropin)

II. EXCEPTION CRITERIA

Coverage for a targeted growth hormone product is provided when any of the following criteria is met:

- Member has tried and experienced documented intolerable adverse events with Humatrope AND Norditropin.
- Member has a documented contraindication to Humatrope or Norditropin or any of their components.
- Nutropin AQ is being prescribed for a patient with chronic kidney disease.

REFERENCES

- Genotropin [package insert]. New York, NY: Pfizer Inc.; December 2016.
- Humatrope [package insert]. Indianapolis, IN: Eli Lilly and Company; December 2016.
- Norditropin [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; February 2018.
- Nutropin AQ [package insert]. South San Francisco, CA: Genentech, Inc.; December 2016.
- Saizen [package insert]. Rockland, MA: EMD Serono Inc.; December 2016.
- Zomacton [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc.; July 2018.
- Omnitrope [package insert]. Princeton, NJ: Sandoz Inc.; October 2014.